CareDx, Inc. (NASDAQ:CDNA) is set to announce second quarter earning results on Tuesday 4th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, CDNA to report 2Q20 loss of $ 0.04 per share from revenue of $ 35.61 million.
For the full year, analysts anticipate top line of $ 155.11 million, while looking forward to loss of $ 0.02 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 165.00 million ~ $ 168.00 million
Click Here For More Historical Outlooks Of CareDx, Inc.
Previous Quarter Performance
CareDx, Inc. disclosed for the first quarter of per share, from the revenue of $ 38.38 million. The quarterly revenues compared with the same quarter last year. The consensus estimates are income of $ 0.03 per share from $ 37.99 million in revenue. The bottom line results missed street analysts by $ 0 or , at the same time, top line results outshined analysts by $ 0.39 million or 1.03 percent.
Stock Performance
According to the previous trading day, closing price of CDNA was $ 33.66, representing a 158.13 % increase from the 52 week low of $ 13.04 and a 7.58 % decrease over the 52 week high of $ 36.42.
The company has a market capital of $ 1.64 billion and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CDNA” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 19th June 2020, maintained by HC Wainwright at Buy rating, with $ 37.00 target price.
Conference Call
CareDx, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.caredxinc.com
CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide. The company develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell-free DNA test initially used for kidney transplant patients.
